Newsfeeds - Spark Newswire

2 minute read

Aptinyx Reports Results From Phase 2b Study Of NYX-2925 In Painful Diabetic Peripheral Neuropathy; Co. Reports ‘NYX-2925 did not achieve the primary endpoint of the study’

Today, 8:02 PM

Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase 2b clinical study

APTX

3 minute read

12 Health Care Stocks Moving In Thursday’s Intraday Session

By Benzinga Insights

Today, 8:02 PM

APTX

1 minute read

Earnings

Aptinyx: Q4 Earnings Insights

By Benzinga Insights

Today, 8:02 PM

Aptinyx (NASDAQ:APTX) reported its Q4 earnings results on Wednesday, March 23, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Aptinyx beat estimated earnings by 17.14%, reporting an EPS of $-0.29 versus an estimate of $-0.35.

APTX

1 minute read

Aptinyx Q4 EPS $(0.29) Beats $(0.35) Estimate

By Benzinga Newsdesk

Today, 8:02 PM

Aptinyx (NASDAQ:APTX) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.35) by 17.14 percent. This is a 45 percent decrease over losses of $(0.20) per share from the same

APTX

4 minute read

Earnings Scheduled For March 23, 2022

By Benzinga Insights

Today, 8:02 PM

Companies Reporting Before The Bell • AYRO (NASDAQ:AYRO) is expected to report earnings for its fourth quarter.

AGFY

1 minute read

Earnings

Earnings Preview For Aptinyx

By Benzinga Insights

Today, 8:02 PM

Aptinyx (NASDAQ:APTX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-23. Here's what investors need to know before the announcement. Analysts estimate that Aptinyx will report an earnings per share (EPS) of $-0.35.

APTX

3 minute read

The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings

By Shanthi Rexaline

Today, 8:02 PM

Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment during the week.

APLT

1 minute read

SVB Leerink Maintains Outperform on Aptinyx, Lowers Price Target to $10

By Benzinga Newsdesk

Today, 8:02 PM

SVB Leerink analyst Marc Goodman maintains Aptinyx (NASDAQ:APTX) with a Outperform and lowers the price target from $12 to $10.

APTX

2 minute read

Aptinyx Initiates Phase 2b Study Of NYX-783 In Patients With Post-Traumatic Stress Disorder

By Benzinga Newsdesk

Today, 8:02 PM

APTX

3 minute read

Mid-Afternoon Market Update: Nasdaq Falls Over 1%; Reata Pharmaceuticals Shares Plummet

By Lisa Levin

Today, 8:02 PM

Toward the end of trading Thursday, the Dow traded up 0.17% to 35,814.21 while the NASDAQ fell 1.13% to 15,608.30. The S&P also fell, dropping 0.28% to 4,688.20.

APTX